IGC Pharma reaches the enrollment event that converts a multi-year Alzheimer's agitation program from a recruiting story into a data story, and the equity now prices that conversion against a cash position that barely covers a month of trial closeout. The lead candidate, IGC-AD1, is an oral cannabinoid liquid in the CALMA Phase 2 study for agitation in Alzheimer's dementia. During the second quarter the trial hit its original randomization target. Subsequent site activity moved the study into a planned over-enrollment phase ahead of follow-up, database lock, and unblinding. The investment debate is whether a late-year topline can re-rate a micro-cap whose operating cash and working-capital deficit leave almost no buffer between a clean readout and another high-cost financing. The market already treats the name as a call on that readout rather than as a going commercial franchise.
The cash print is the other half of the story. Mid-year cash sat at $331 thousand. That balance sits against a working-capital deficit of about $2 million. Management converted roughly $1.15 million of officer claims into equity rather than take cash out of the company. Those two facts together describe a sponsor that is rationing liquidity into the last yards of a Phase 2 closeout. The wellness and white-label sales line that still appears on the income statement is not a franchise that funds this trial. It is residual volume from an earlier identity as a consumer-products hybrid, and the gross margin on that volume compressed as manufacturing moved to third parties.
The second-quarter loss widened because research spending on CALMA and TGR-63 rose while the small sales base shrank. Revenue was $265 thousand against $328 thousand a year earlier. Net loss reached about $3 million. First-half operating cash outflow was $2.6 million, covered by a mix of equity issuance and original-issue-discount notes from Vanquish and FirstFire. Those notes carry default conversion at a discount to the lowest recent print, which is the financing architecture of a company that cannot yet borrow on the strength of the asset. The O-Bank revolving line remains undrawn and is subject to a monthly cap and a mid-2027 expiry, so it is a constrained bridge rather than a war chest.
The market capitalizes the equity at roughly $30 million, which is almost entirely option value on CALMA rather than cash or earnings. The bull case treats the small-N interim CMAI signal as a preview of a partnerable Phase 2 win in a large agitation market that still has only one approved antipsychotic. The bear case treats that interim as an underpowered look that does not survive full enrollment, while the note stack and the at-the-market program consume the residual option before a partner arrives. Both readings are live. The four variables that resolve them are CALMA Confirmation, the Liquidity Bridge, Partnerability After Data, and Dilution Velocity.